Literature DB >> 27413094

Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Mordechai Grupper1, Joseph L Kuti1, David P Nicolau2.   

Abstract

Beta-lactam antibiotics serve as a cornerstone in the management of bacterial infections because of their wide spectrum of activity and low toxicity. Since resistance rates among bacteria are continuously on the rise and the pipeline for new antibiotics does not meet this trend, an optimization of current beta-lactam treatment is needed. This review provides an overview of optimization through use of prolonged- and continuous-infusion dosing strategies compared with more traditional intermittent infusions. Included is an overview of the scientific basis for using these nontraditional prolonged- and continuous-infusion-based regimens, with a focus on major areas in which the clinical laboratory can support the clinical use of these regimens.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27413094      PMCID: PMC5010748          DOI: 10.1128/CMR.00022-16

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  127 in total

1.  Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.

Authors:  William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

3.  Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Authors:  Leonardo Lorente; Alejandro Jiménez; María M Martín; José Luis Iribarren; Juan José Jiménez; María L Mora
Journal:  Int J Antimicrob Agents       Date:  2009-01-15       Impact factor: 5.283

4.  High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.

Authors:  F Lamoth; T Buclin; A Pascual; S Vora; S Bolay; L A Decosterd; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.

Authors:  Bernard Georges; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

6.  Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.

Authors:  Leonardo Lorente; Alejandro Jiménez; Salome Palmero; Juan José Jiménez; José Luís Iribarren; Melitón Santana; María M Martín; Maria L Mora
Journal:  Clin Ther       Date:  2007-11       Impact factor: 3.393

8.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Performance of two resin-containing blood culture media in detection of bloodstream infections and in direct matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) broth assays for isolate identification: clinical comparison of the BacT/Alert Plus and Bactec Plus systems.

Authors:  Barbara Fiori; Tiziana D'Inzeo; Viviana Di Florio; Flavio De Maio; Giulia De Angelis; Alessia Giaquinto; Lara Campana; Eloisa Tanzarella; Mario Tumbarello; Massimo Antonelli; Maurizio Sanguinetti; Teresa Spanu
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

10.  Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans.

Authors:  K E Bowker; H A Holt; R J Lewis; D S Reeves; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

View more
  10 in total

1.  Should Prolonged Infusion of β-Lactams Become Standard of Practice?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2017 Mar-Apr

2.  Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Authors:  Christopher M Rubino; Sujata M Bhavnani; Jeffery S Loutit; Elizabeth E Morgan; Dan White; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.

Authors:  Taylor A Imburgia; Michelle L Kussin
Journal:  J Pediatr Pharmacol Ther       Date:  2022-03-21

4.  Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.

Authors:  Jaclyn A Cusumano; Kathryn E Daffinee; Emily C Piehl; Mónica García-Solache; Charlene Desbonnet; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

5.  Evaluation of Prolonged Versus Continuous Infusions of Piperacillin/Tazobactam During Shortages of Small Volume Parenteral Solutions.

Authors:  Emily Tschumper; Kaitlyn Dupuis; Kim McCrory; Wes Pitts
Journal:  J Pharm Technol       Date:  2021-07-23

6.  Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles.

Authors:  Mordechai Grupper; David P Nicolau; Jaber Aslanzadeh; Linda K Tanner; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2017-10-11       Impact factor: 5.948

7.  Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.

Authors:  Nhu T Q Nguyen; Emmanuelle Gras; Nguyen D Tran; Nhi N Y Nguyen; Hanh T H Lam; William J Weiss; Thien N M Doan; Binh An Diep
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

8.  Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.

Authors:  Todd A Riccobene; Timothy J Carrothers; William Knebel; Susan Raber; Phylinda L S Chan
Journal:  Clin Pharmacol Drug Dev       Date:  2021-01-19

9.  Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.

Authors:  Abdul Haseeb; Hani Saleh Faidah; Saleh Alghamdi; Amal F Alotaibi; Mahmoud Essam Elrggal; Ahmad J Mahrous; Safa S Almarzoky Abuhussain; Najla A Obaid; Manal Algethamy; Abdullmoin AlQarni; Asim A Khogeer; Zikria Saleem; Muhammad Shahid Iqbal; Sami S Ashgar; Rozan Mohammad Radwan; Alaa Mutlaq; Nayyra Fatani; Aziz Sheikh
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

10.  Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.

Authors:  Stan J F Hartman; Parth J Upadhyay; Nienke N Hagedoorn; Ron A A Mathôt; Henriëtte A Moll; Michiel van der Flier; Michiel F Schreuder; Roger J Brüggemann; Catherijne A Knibbe; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2021-05-26       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.